CN100375621C - Vinorelbine liposome micro ball injection and its prepn - Google Patents
Vinorelbine liposome micro ball injection and its prepn Download PDFInfo
- Publication number
- CN100375621C CN100375621C CNB2005101155566A CN200510115556A CN100375621C CN 100375621 C CN100375621 C CN 100375621C CN B2005101155566 A CNB2005101155566 A CN B2005101155566A CN 200510115556 A CN200510115556 A CN 200510115556A CN 100375621 C CN100375621 C CN 100375621C
- Authority
- CN
- China
- Prior art keywords
- oil
- injection
- vinorelbine
- water
- oil phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960002066 vinorelbine Drugs 0.000 title claims abstract description 100
- 239000007924 injection Substances 0.000 title claims abstract description 92
- 238000002347 injection Methods 0.000 title claims abstract description 92
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 title claims abstract 25
- 239000002502 liposome Substances 0.000 title claims description 19
- 239000011806 microball Substances 0.000 title claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 95
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- 239000004005 microsphere Substances 0.000 claims abstract description 20
- -1 vinorelbine lipid Chemical class 0.000 claims abstract description 17
- 239000003921 oil Substances 0.000 claims description 146
- 235000019198 oils Nutrition 0.000 claims description 146
- 239000012071 phase Substances 0.000 claims description 96
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 75
- 239000008215 water for injection Substances 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 53
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 50
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 39
- 239000000787 lecithin Substances 0.000 claims description 39
- 235000010445 lecithin Nutrition 0.000 claims description 39
- 229940067606 lecithin Drugs 0.000 claims description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 36
- 238000005360 mashing Methods 0.000 claims description 34
- 239000003963 antioxidant agent Substances 0.000 claims description 32
- 230000003078 antioxidant effect Effects 0.000 claims description 32
- 235000006708 antioxidants Nutrition 0.000 claims description 32
- 229930003427 Vitamin E Natural products 0.000 claims description 25
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 25
- 235000011187 glycerol Nutrition 0.000 claims description 25
- 239000004094 surface-active agent Substances 0.000 claims description 25
- 239000011709 vitamin E Substances 0.000 claims description 25
- 235000019165 vitamin E Nutrition 0.000 claims description 25
- 229940046009 vitamin E Drugs 0.000 claims description 25
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 24
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 24
- 210000003022 colostrum Anatomy 0.000 claims description 23
- 235000021277 colostrum Nutrition 0.000 claims description 23
- 238000002156 mixing Methods 0.000 claims description 23
- 239000002245 particle Substances 0.000 claims description 23
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 23
- 229920000053 polysorbate 80 Polymers 0.000 claims description 23
- 235000012424 soybean oil Nutrition 0.000 claims description 23
- 239000003549 soybean oil Substances 0.000 claims description 23
- 239000008346 aqueous phase Substances 0.000 claims description 21
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 20
- 230000008859 change Effects 0.000 claims description 20
- 238000000386 microscopy Methods 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 19
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- 238000001802 infusion Methods 0.000 claims description 18
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 238000005070 sampling Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 18
- 239000002738 chelating agent Substances 0.000 claims description 17
- 230000003204 osmotic effect Effects 0.000 claims description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000004615 ingredient Substances 0.000 claims description 12
- 235000010265 sodium sulphite Nutrition 0.000 claims description 12
- 229920001983 poloxamer Polymers 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 230000001105 regulatory effect Effects 0.000 claims description 10
- 235000010323 ascorbic acid Nutrition 0.000 claims description 9
- 229960005070 ascorbic acid Drugs 0.000 claims description 9
- 239000011668 ascorbic acid Substances 0.000 claims description 9
- 239000004201 L-cysteine Substances 0.000 claims description 8
- 235000013878 L-cysteine Nutrition 0.000 claims description 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 8
- 239000000194 fatty acid Substances 0.000 claims description 8
- 229930195729 fatty acid Natural products 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 7
- 229920000136 polysorbate Polymers 0.000 claims description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 239000010775 animal oil Substances 0.000 claims description 6
- 239000009969 fructus bruceae Substances 0.000 claims description 6
- 235000019485 Safflower oil Nutrition 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- 235000005713 safflower oil Nutrition 0.000 claims description 5
- 239000003813 safflower oil Substances 0.000 claims description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 claims description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 3
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 3
- 229920002651 Polysorbate 85 Polymers 0.000 claims description 3
- 241000282894 Sus scrofa domesticus Species 0.000 claims description 3
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 3
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 3
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 3
- 229940101027 polysorbate 40 Drugs 0.000 claims description 3
- 229940113124 polysorbate 60 Drugs 0.000 claims description 3
- 229940113171 polysorbate 85 Drugs 0.000 claims description 3
- 210000002374 sebum Anatomy 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical group OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 claims description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 56
- 230000000694 effects Effects 0.000 abstract description 13
- 150000002632 lipids Chemical class 0.000 abstract description 11
- 231100000419 toxicity Toxicity 0.000 abstract description 9
- 230000001988 toxicity Effects 0.000 abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract 2
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 73
- 229940090044 injection Drugs 0.000 description 70
- 210000001519 tissue Anatomy 0.000 description 31
- 239000000839 emulsion Substances 0.000 description 22
- 235000005687 corn oil Nutrition 0.000 description 17
- 229940079593 drug Drugs 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 230000007794 irritation Effects 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 9
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 8
- 239000004380 Cholic acid Substances 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 8
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 8
- 235000019416 cholic acid Nutrition 0.000 description 8
- 229960002471 cholic acid Drugs 0.000 description 8
- 238000005538 encapsulation Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229960000502 poloxamer Drugs 0.000 description 7
- 229960002166 vinorelbine tartrate Drugs 0.000 description 7
- GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 7
- 206010018910 Haemolysis Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 230000008588 hemolysis Effects 0.000 description 6
- 210000003314 quadriceps muscle Anatomy 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 230000002949 hemolytic effect Effects 0.000 description 5
- 238000011587 new zealand white rabbit Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 229940111604 vinorelbine injection Drugs 0.000 description 5
- 206010002198 Anaphylactic reaction Diseases 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000036783 anaphylactic response Effects 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 239000005642 Oleic acid Substances 0.000 description 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
- 240000007711 Peperomia pellucida Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 235000016236 parenteral nutrition Nutrition 0.000 description 3
- 239000003182 parenteral nutrition solution Substances 0.000 description 3
- 240000006409 Acacia auriculiformis Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108010004103 Chylomicrons Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 239000000823 artificial membrane Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229960003964 deoxycholic acid Drugs 0.000 description 2
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 229960002969 oleic acid Drugs 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- DUVVGYBLYHSFMV-YGEZULPYSA-N 4-methyl-n-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]carbamoyl]benzamide Chemical compound C1=CC(C)=CC=C1C(=O)NC(=O)N[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DUVVGYBLYHSFMV-YGEZULPYSA-N 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 101100489867 Mus musculus Got2 gene Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229950004777 sodium calcium edetate Drugs 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a vinorelbine lipid microsphere injection and a preparation method thereof. 90% to 98% of vinorelbine is coated in an oil phase of lipid microspheres and an oil-water interface film, and thereby, the toxicity and the stimulation of the vinorelbine used in clinics are greatly reduced, and the antitumor treatment effect is enhanced. The medicine of the present invention is used as an antitumor medicine, is taken in an injection mode and has the advantages of low stimulation, low toxicity and high efficiency.
Description
Technical field
The present invention relates to medical technical field, relate to a kind of Lipid micropellet parenteral solution of auspicious bank of Changchun and its preparation method in particular.
Background technology
Along with the development and the progress of medicine and pharmacology technology, the mankind have controlled the infectious disease that in the past mainly threatens human health basically, then become the archenemy of human health gradually such as noninfectiouss such as tumor, cardiovascular and cerebrovascular diseases.According to 1997 years of World Health Organization (WHO), because of cancer mortality 6,300,000 people are arranged approximately in the whole world 5,800,000,000 populations in 1996, account for 12% of total death toll, wherein nearly 60% dies from pulmonary carcinoma, gastric cancer, breast carcinoma, colorectal carcinoma, oral cancer, hepatocarcinoma, cervical cancer and the esophageal carcinoma, is the second largest cause of the death that is only second to cardiovascular disease.The annual tumor patient of newly making a definite diagnosis in the whole world is all more than 1,030 ten thousand people since 1996, to the end of the year 1999 whole world tumor patient sum exceeded 4,000 ten thousand people.World Health Organization's calendar year 2001 report, world's cancer morbidity and mortality rate have risen 22% than the nineteen ninety, also will rise about 50% in 20 years from now on.The epidemiological study prompting, China not only tumor mortality rate is obvious ascendant trend, and the characteristics that have developing country and developed country spectrum occurred frequently concurrently and deposit, and China increases tumor patient 160-170 ten thousand people newly every year in recent years, and Estimate of Total Number is about 4,500,000 people.Therefore, the exploitation of antitumor drug is the most important thing of many pharmacy worker's researchs.In addition, because most antitumor drug untoward reaction are serious, body and mind to the patient in therapeutic process causes very major injury, therefore how when improving curative effect of medication, improve patient's life quality and become new direction and the emphasis of present antitumor drug research gradually thereby reduce the zest of medicine and toxicity.
Vinorelbine is a kind of semisynthetic vinca anti-cancer agent, the active anticancer height, and antitumor spectra is wide, and through external clinical research, single medicine or drug combination treatment nonsmall-cell lung cancer, breast carcinoma, ovarian cancer, malignant lymphoma etc. have shown outstanding curative effect.But the injection of this medicine has bigger zest when clinical use, such as the vinorelbine tartrate injection of the present clinical use commodity Navelbine by name of company (French Pierre Fabre) is hypertonicity solution, and it is acid that its aqueous solution is, too high or medicinal liquid exosmoses and can produce bigger toxicity to transfusion vein and stimulate as local concentration, and can cause phlebitic generation.Its phlebitis incidence rate 47.2% of research is arranged.Toxicity mainly is that leukocyte count descends overall reaction rate 72%.Therefore the injection that uses clinically at present all requires and must be diluted to 50mL with normal saline earlier, in the short time (6-10 minute), import through vein, use 250-500 mL normal saline flushing vein then, and must confirm that injection needle can start injection at intravenous, in case medicine liquid leakage should stop injection immediately, surplus medicine changes vein in addition and injects.This brings a lot of miseries to the patient undoubtedly, brings a lot of inconvenience on using, and has limited vinorelbine generally popularization and application clinically.
Therefore in view of above-mentioned characteristic, bring into play clinical efficacy better for making vinorelbine, the research and development novel form, cover the zest of medicine with the advantage of novel form, the toxicity that reduces medicine is to give full play to the vinorelbine anti-tumor activity, and this undoubtedly will be significant to further promotion and the application of popularization vinorelbine in clinical.
Lipomul is applied to clinical nearly half a century as the important supply mode of the outer energy of intestinal.Between 1920～nineteen thirty, Japanese scholar was that raw material, lecithin are emulsifying agent with Oleum Ricini once, and at first the synthetic lipomul is tried out in animal; The U.S. has released Lipomul based on cotton seed oil the fifties and has been applied to patient but all fails to promote because of serious toxicity.1964, the U.S. stopped to produce and using lipomul.But in Europe, with Wretling be a collection of scholar of representative to study untiringly and use based on soybean oil, with the lecithin be emulsifying agent, be the lipomul Introlipid of isotonic agent with glycerol.1962, Introlipid was used for clinical in Sweden by official approval.1967, article " lipomul the is applied to complete intravenous nutrition " comprehensive summing up of delivering by Hallberg etc. experiment and the clinical research of Introlipid, prove that it is applied to clinical is safe and reliable, and proposed the criterion of Introlipid clinical practice." obtaining growth, growth and positive nitrogen balance under the long-term complete parenteral nutrition " literary composition that this literary composition and nineteen sixty-eight Dudrick etc. deliver is acknowledged as parenteral nutrition is developed into two pieces of classical works that routine clinical is used significant impact.After this more than 20 year, Introlipid obtained extensive use all over the world, and developed countries such as moral, method, Japan and the United States have developed national lipomul in succession.1976, U.S. appropriate authorities have ratified lipomul again can be in routine clinical application.At present, kind of a lipomul appeared on the market surplus the whole world had 20 at least.China is also joint the end of the eighties and Sweden Kabi company, and mass production Introlipid is for clinical practice.1973, that Solassol etc. have at first introduced is three-in-one, and (All-in-one, the AIO) notion of solution proved that lipomul and all other nutritional solutions can be mixed in the bottle or in the bag, can keep stable and nutritional support effect at certain condition with in the time.After this promoted AIO transfusion plastic bag, the preparation and the infusion of parenteral nutrition liquid simplified in this simple but relevant improvement greatly, for the wide clinical application of lipomul has been widened road.Up to the present, it is oil-in-water type (oil in water, the o/w) submicronized emulsion of emulsifying agent as decentralized photo with the Ovum Gallus domesticus Flavus lecithin that common lipomul is meant with fatty glyceride.Because the Chylomicron that exists behind the composition of lipomul emulsion droplet and particle diameter and the oral fat group food is very similar, therefore it has been generally acknowledged that the emulsion droplet of lipomul is also similar with Chylomicron in the intravital behavior of people in blood.Along with the further investigation to lipomul, it is also just bringing into play more and more important effect at pharmaceutical field.
The special physicochemical property and the hypotoxicity of lipomul have determined it to can be used as fat-soluble medicine, particularly the good carrier of cancer therapy drug, anaesthetic and anti-inflammatory drug.The normal method that adopts is the lipid core part that pharmaceutical pack is wrapped in lipomul because this structure also is similar to microsphere, so lipid microsphere (LipidMicrosphere, title LM) is also arisen at the historic moment.It is generally acknowledged that lipid microsphere is by medicine is dissolved in the fatty oil, and after phospholipid emulsifying is scattered in water, make, be a kind of be soft substrate and the microparticulate system sealed by immobilized artificial membrane with fatty oil, mean diameter is about 200nm.The structural representation of LM is seen accompanying drawing 1.
LM has many physical chemistry and advantage biologically:
1. be the good carrier of fat-soluble medicine.Clinical many medicine poorly water-solubles must rely on the effect of organic solvent competence exertion, and organic solvent not only itself have certain toxicity, also may the interference medicament effect.
2. can effectively increase stability of drug.In the pastille lipid microsphere, quite a few drug distribution is arranged in oil phase or oil-water interfacial film, avoided directly contacting with water.Change responsive medicine for facile hydrolysis or to pH, this " isolation " played the effect that increases stability.
3.LM Chinese medicine partly is wrapped in oil phase or the interfacial film, avoided with body fluid until contacting, thereby reduced issuable part of medicine self and blood vessel irritation.In addition, medicine is by slowly discharge the untoward reaction that can avoid medicine to cause owing to the initial stage excessive concentration in the oil phase when injection in vivo.
4. the small particle of particle diameter about 200 nm can be engulfed by the phagocyte of the reticular tissue system of body and be trapped in the reticular tissue system (as liver, lung etc.), have targeting, this characteristics for antitumor drug improve drug effect, to reduce toxic and side effects particularly important.
We are decided to be encapsulation ratio with the medicine total amount of oil phase and emulsifying agent layer, and assay method is as follows:
(1) the accurate vinorelbine liposome micro ball 100 μ L that draw of the mensuration of medicine total amount add 2mL chromatographically pure ether in the 10mL measuring bottle, add chromatographically pure methanol to scale, mixing, ultrasonic 10min, 0.22 μ m filtering with microporous membrane, get subsequent filtrate, measure, record peak area A with the HPLC method
T
(2) mensuration of aqueous phase medicament contg is got vinorelbine liposome micro ball 4mL, put in the supercentrifuge with 46 000rpm (=approx.10,7000g) centrifugal 4h, temperature 10C, take off layer settled solution 100 μ L in the 10mL measuring bottle, be diluted to scale with methanol, mixing, 0.22 μ m filtering with microporous membrane, get subsequent filtrate, measure, record peak area A with the HPLC method
w
(3) encapsulation ratio=preparation of Chinese medicine total amount-aqueous phase medication amount
Computing formula is as follows:
Vinorelbine O-I=1-vinorelbine W
Vinorelbine W=(1-W oil) * Cw/CT=(1-W oil) * Aw/AT
Wherein: vinorelbine O-I is the distribution sum of medicine at oil phase and emulsifying agent layer;
Vinorelbine W is the distribution of medicine at aqueous phase;
Cw is the aqueous phase drug level;
CT is the preparation of Chinese medicine total concentration;
W oil is the percentage by weight of oil phase in the preparation.
So, encapsulation ratio=[1-(1-W oil) * Cw/CT] * 100%=[1-(1-W oil) * Aw/AT] and * 100%
The patent of application number 200410065105.1 and application number 200510038178.6 provides a kind of prescription and preparation method for preparing injection for intravenous with vinorelbine emulsion, but the vinorelbine medicine in these patents is not wrapped in oil phase or the interfacial film effectively, thus can't reach reduction to the zest of blood vessel, improve purpose such as curative effect; In addition, because the easy oxidative degradation of vinorelbine, the unstability of vinorelbine medicine also is the major issue that present vinorelbine medicine is deposited in actual applications, more than two patents effective solution is not provided yet.
Summary of the invention
Purpose of the present invention is exactly to overcome the defective that existing vinorelbine dosage form exists, and a kind of vinorelbine liposome micro ball injection of injection for intravenous is provided, and its preparation method also is provided simultaneously.This vinorelbine liposome micro ball injection provided by the invention, wherein vinorelbine can be wrapped in oil phase and the oil-water interfacial film well, and therefore, this lipide microsphere injection has reduced zest and the toxic and side effects of vinorelbine to blood vessel, good stability, evident in efficacy.
The present invention relates to a kind of Lipid micropellet parenteral solution of auspicious bank of Changchun and its preparation method.
Lipide microsphere injection provided by the invention is made up of vinorelbine, oil-soluble medium, surfactant, oil phase solubilizing agent, osmotic pressure regulator, antioxidant, metal-chelator and water for injection; The percentage by weight of its composition is:
Vinorelbine 0.001%～10%
Oil-soluble medium 2%～50%
Surfactant 0.2%～10%
Osmotic pressure regulator 0.1%～10%
Oil phase solubilizing agent 0.1%～5%
Antioxidant 0.001%～2%
Metal-chelator 0.001%～2%
All the other are water for injection.
Vinorelbine among the present invention is vinorelbine alkali or the various salt that obtained by vinorelbine alkali and available acid reaction pharmaceutically; The oil-soluble medium is a kind of or its mixture in mineral oil, vegetable oil, animal oil, quintessence oil or the artificial oil; Described surfactant is a phospholipid, polyoxyethylene sorbitan fatty acid ester tween Tween, pluronic poloxamer, enuatrol, oleic acid, cholic acid, deoxycholic acid or its mixture; Osmotic pressure regulator is a glycerol, sorbitol, mannitol, glucose or its mixture; The oil phase solubilizing agent is 10-hydroxyl-2-decylenic acid, fatty acid esters of sorbitan Span or its mixture; Antioxidant is water solublity antioxidant: sodium sulfite, sodium pyrosulfite, sodium sulfite, ascorbic acid, L-cysteine; Oil-soluble antioxidant: vitamin E or its mixture; The metal chelating is disodium EDTA EDTA, calcium disodium salt of EDTA or its mixture.
Preferred version of the present invention is: vinorelbine is tartrate, maleate, lactate, malate, hydrochlorate, sulfate, the phosphate of vinorelbine; Vegetable oil in the described oil-soluble medium is a safflower oil, soybean oil, Semen Maydis oil, Semen Coicis oil, Oleum Fructus Bruceae, Oleum Ricini, Oleum Gossypii semen, Oleum Cocois, Petiolus Trachycarpi oil, MCT Oil MCT or its mixture; Animal oil is sebum, Adeps Sus domestica, fish oil, sperm oil and composition thereof; Phospholipid in the described surfactant is lecithin, fabaceous lecithin or its mixture; Tween in the described surfactant is a polysorbas20, polysorbate40, polysorbate60, Tween 80, polysorbate85, or its mixture; The pluronic of described surfactant is pluronic F68; Fatty acid esters of sorbitan Span in the described oil phase solubilizing agent is Span20,40,60,80, and perhaps its mixture.
The vinorelbine of 90%-98% is wrapped in oil phase or the oil-water interfacial film in the lipide microsphere injection of vinorelbine of the present invention.
To better implement the present invention, the composition of injection can be:
Vinorelbine 0.01%～5%
Oil-soluble medium 5%～30%
Surfactant 0.5%～5%
Osmotic pressure regulator 0.5%～5%
Oil phase solubilizing agent 0.2%～3%
Antioxidant 0.01%～1%
Metal-chelator 0.01%～1%
All the other are water for injection.
Preferred version of the present invention is:
Vinorelbine 0.05%～1%
Oil-soluble medium 8%～20%
Surfactant 1%～3%
Osmotic pressure regulator 1%～5%
Oil phase solubilizing agent 0.4%～2%
Antioxidant 0.05%～0.5%
Metal-chelator 0.02%～0.5%
All the other are water for injection.
A preferred version more of the present invention is:
The composition of this injection is by weight percentage:
Vinorelbine 0.1%
Oil-soluble medium (oil phase) (soybean oil/MCT Oil=2/8) 10%
Surfactant is lecithin 1.2%Tween-80 0.2% enuatrol 0.1%
Osmotic pressure regulator is a glycerol 2.5%
The oil phase solubilizing agent is 10-hydroxyl-2-decylenic acid 0.5%Span80 0.1%
Antioxidant is L-cysteine 0.2% vitamin E 0.05%
Metal-chelator is EDTA 0.05%
All the other are water for injection.
The present invention also provides the preparation method of vinorelbine liposome micro ball injection, comprise following steps: mix surfactant, osmotic pressure regulator, water solublity antioxidant, the metal chelating of recipe quantity (1) with the water for injection that is preheated to 70-80 ℃, change in the tissue mashing machine, stir, until each composition dissolving, get water; With in the oil-soluble antioxidant of recipe quantity, the oil-soluble medium that the oil phase solubilizing agent adds to recipe quantity, be heated to 70-80 ℃ simultaneously, dissolving, oil phase; (2) oil phase is added aqueous phase, change in the tissue mashing machine, stir,, get colostrum until the oil phase homodisperse; (3) the recipe quantity vinorelbine is added to above-mentioned Ruzhong just, use sodium hydroxide, hydrochloric acid is regulated pH value 7-9, and adding is preheated to 70-80 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 1-10 time, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Its preferred version is: mix surfactant, osmotic pressure regulator, water solublity antioxidant, the metal chelating of recipe quantity (1) with the water for injection that is preheated to 70 ℃, changes in the tissue mashing machine, stirs, and until each composition dissolving, gets water; With in the oil-soluble antioxidant of recipe quantity, the oil-soluble medium that the oil phase solubilizing agent adds to recipe quantity, be heated to 70 ℃ simultaneously, dissolving, oil phase; (2) oil phase is added aqueous phase, change in the tissue mashing machine, stir,, get colostrum until the oil phase homodisperse; (3) the recipe quantity vinorelbine is added to above-mentioned Ruzhong just, use sodium hydroxide, hydrochloric acid is regulated pH value 8.5, and adding is preheated to 70 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Using the acceptable material of term " oil " indication one big class physiology among the present invention, can be mineral oil, vegetable oil, animal oil, quintessence oil, artificial oil, or its mixture.Therefore, use term " oil " in order to refer to the very material of different chemical character that has of a wide region herein.With type or functional classification oil the time, as mineral oil source from oil and comprise fat or cerul hydrocarbon, aromatic hydrocarbon or blended fat and aromatic radical hydrocarbon.The oil such as the refined paraffin wax wet goods that in the mineral oil classification, also comprise petroleum derivation.In the vegetable oil classification, oil is mainly derived from seed or nut, and comprises drying oil such as Semen Lini and Oleum Verniciae fordii; Semi-drying oil such as safflower oil and soybean oil; Non-drying oil such as Oleum Ricini, Oleum Gossypii semen, Oleum Cocois and Petiolus Trachycarpi oil.In the animal oil classification, oil is usually from sebum, Adeps Sus domestica.Aqueous animal oil comprises fish oil, the spermaceti wet goods.Be preferably long-chain fat acid glyceride, medium chain length fatty acid triglyceride, and composition thereof.
Used surfactant can be various nonionic surfactant, anionic surfactant or amphoteric ionic surfactant, is generally phospholipid, tween (Tween), pluronic (poloxamer), enuatrol, oleic acid, cholic acid, deoxycholic acid and composition thereof.Described phospholipid is selected from lecithin, fabaceous lecithin, and composition thereof.Described tween is selected from polysorbas20, polysorbate40, and polysorbate60, Tween 80, polysorbate85, and composition thereof.Be preferably lecithin, fabaceous lecithin, enuatrol, oleic acid, Tween 80, pluronic F68, and composition thereof.
The oil phase solubilizing agent is fatty acid esters of sorbitan (Span) class nonionic surfactant, 10-hydroxyl-2-decylenic acid, and composition thereof.
Antioxidant is water solublity antioxidant: sodium sulfite, sodium pyrosulfite, sodium sulfite, ascorbic acid, L-cysteine; Oil-soluble antioxidant: vitamin E, and composition thereof.
The metal chelating is disodium edetate (disodium EDTA), sodium calcium edetate (calcium disodium salt of EDTA), and composition thereof.
Vinorelbine is an alkaloid, and adding fat-soluble sour 10-hydroxyl-2-decylenic acid and its reaction in the prescription can increase that it is fat-soluble; Add less surfactant fatty acid esters of sorbitan (Span) class of hydrophile-lipophile balance value (HLB value) in the prescription and also can increase the fat-soluble of medicine.Adopt high pressure homogenize on the preparation technology, high speed airflow bump forms a kind of supersonic speed and stirs, and makes medicine dissolving and be penetrated in the oil-water interfacial film with molecular forms rapidly.
After the present invention makes lipide microsphere injection to the medicine vinorelbine, because the pharmaceutical pack more than 90% is wrapped in oil phase or the oil-water interfacial film, can avoid contacting, thereby reduce medicine at zest that the injection site produced and the general toxicity that causes therefrom with the direct of blood vessel or body fluid.The acute toxicity tests shows: compare vinorelbine liposome micro ball injection toxicity with commercially available vinorelbine liquid drugs injection injection and reduce greatly.
According to the literature, particle diameter can concentrate in reticuloendothelial system abundant liver and pulmonary with blood circulation after injection enters human body at the microgranule about 200nm, therefore particle diameter has the guiding distribution performance of relative targeting to the reticular tissue cell system at the medicine carrying lipid microsphere of this scope, this for the curative effect that improves cancer therapy drug, reduce that it is highly beneficial to Normocellular infringement, thereby the untoward reaction that can lower general, increase the useful effect of medicine.
The antitumor drug vinorelbine liposome micro ball injection that the present invention is prepared has the characteristics of low irritant, hypotoxicity, high efficiency.
In addition, the most inappetence of patient after the chemotherapy, digestive function is low, should in time supplement the nutrients and energy.Lipide microsphere injection mainly is made up of oil phase, emulsifying agent and isoosmotic adjusting agent etc., it can provide essential fatty acid and energy for body, keep the constant of cellularity and body fat tissue, this obviously is comparatively ideal selection concerning supply with the fatty patient who is difficult to tolerate through gastrointestinal.
The investigation of vinorelbine dilution stability
For satisfying the needs of different dosing regimes, when using clinically, injectable drug often needs dilution back administration, and diluent media commonly used comprises sodium chloride injection (0.9%) and glucose injection (5.4%).Because lipid microsphere is different from common solution type injection agent, it all belongs to Unstable Systems on thermodynamics and kinetics, diluent media and dilution time can produce material impact to its stability, and bibliographical information is arranged, if the vinorelbine injection dilutes with glucose, can precipitate, so this preparation dilutes and the time that can use safely after definite the dilution with normal saline.
Three batches of lipide microsphere injection samples with the dilution of 4 times of amount normal saline, are surveyed its particle diameter respectively at sampling in 0,2,4,6,8,12 hour, and average result is seen accompanying drawing 2.Measured its encapsulation ratio in 0,2,6,12 hour respectively at placing, average result is respectively 94.2%, 93.5%, 86.4% and 80.6%.
Conclusion: determine that by above experimental result during with 4 times of sodium chloride injection (0.9%) dilutions, it is safe and rational using to vinorelbine liposome micro ball injection when clinical use in 2 hours.
The vinorelbine liposome micro ball injection irritation test
(1) blood vessel irritation experiment
Two kinds of different dosage forms of vinorelbine injection are carried out body surface area by clinical application amount (30mg/ time) to convert and draws experimental rabbit with dosage (1.4mg/kg).The dosage of pressing 2ml/kg before the test is with the fresh preparation of aseptic normal saline solution.Select 6 of the healthy new zealand white rabbits of body weight 2.5-3.0kg for use, male and female have concurrently.After iodine tincture and ethanol disinfection were used in the injection site, 3 white rabbits were in auris dextra auricular vein injection vinorelbine liquid drugs injection injection (Cs), and left ear is injected the aseptic normal saline solution of same dose in contrast; 3 white rabbits are in auris dextra auricular vein injection vinorelbine liposome micro ball injection (Cz) in addition, and left ear is injected the aseptic normal saline solution of same dose in contrast, and injection speed is 2.8ml/min (being equivalent to people's clinical injection speed).Once a day, continuous three days, the last administration was after 24 hours, inject air by auricular vein and put to death white rabbit, the response situation of perusal injection site, and dissect rabbit ear blood vessel and surrounding tissue is done paraffin section (entad holding 1cm and 5cm place under the injection site), HE dyeing, light microscopy checking.The result of perusal injection site reaction situation is shown in table-1, and pathological section is checked by disease prevention and control center, Liaoning Province, and presented audit report.
The result: shown in table-1, two kinds of dosage form blood vessel irritation tests of vinorelbine injection perusal.The result shows: the blood vessel irritation of Cz is weaker than Cs; Microscopy report shows: the Cs group has to a certain degree blood vessel irritation to New Zealand white rabbit ear blood vessel, and the Cz group is not seen obvious irritation to New Zealand white rabbit ear blood vessel.
Table-1 blood vessel irritation test perusal
(2) muscle irritation experiment
The dosage of vinorelbine injection converts, the selection of medicine preparation, New Zealand white rabbit the same (totally 4, every kind dosage form 2).Cut off the rabbit hair at quadriceps femoris position, white rabbit both sides, behind iodine tincture and ethanol disinfection, respectively at right lateral thigh musculus quadriceps injection vinorelbine liquid drugs injection injection (Cs) and vinorelbine liposome micro ball injection (Cz) injection 1ml, the physiological saline solution injection of left side quadriceps femoris injection equivalent is injected after 48 hours in contrast, goes into air by auricular vein and puts to death white rabbit, dissect and take out quadriceps femoris, vertically cut, observe the response situation of injection site muscular tissue, determine the order of reaction.
0 grade: no change.
1 grade: mild hyperaemia, its scope is below 0.5cm * l.0cm.
2 grades: moderate hyperemia, its scope is more than 0.5cm * 1.0cm.
3 grades: severe hyperemia, with myodegeneration.
4 grades: necrosis occurs, the brown degeneration is arranged.
5 grades: the popularity necrosis occurs.
Calculate 4 quadriceps femoris order of reaction summations then, test again if the difference of the peak of the quadriceps femoris order of reaction and minimum, then should be got 2 healthy rabbits in addition greater than 2.After obtaining the result, if 4 quadriceps femoris order of reaction summations, think then that the local irritation test of test sample is up to specification less than 10.
The result: the muscle irritation result of the test of two kinds of dosage form injection of vinorelbine is shown in table-2.
The result shows: the muscle irritation of Cz is weaker than Cs.
Table-2 muscle irritation result of the tests
The hemolytic experiment
Get blood 20ml from the common carotid artery of New Zealand white rabbit, place in the flask, stir gently with Glass rod, after several minutes, remove and defibrinate, take out blood, add the equivalent normal saline solution, centrifugal (1500r/min 10min), removes supernatant; Sedimentary erythrocyte adds normal saline solution again and cleans, and is centrifugal.Transparent until supernatant so repeatedly, be made into 2% suspension with normal saline by erythrocytic capacity.
Get 7 of clean tube, numbering adds each liquid in the following table successively respectively, the 6th pipe does not add test liquid as the blank pipe, and the 7th effective distilled water replaces normal saline, shakes up, whether place 37 ℃ of water-baths, observing respectively at 0.5 hour, 1 hour, 2 hours, 3 hours has haemolysis to take place.
The result: the hemolytic experimental result of two kinds of dosage form injection of vinorelbine sees Table-3, shows-4.
Table-3 vinorelbine liquid drugs injection dregs penetrate drips (Cs) hemolytic experimental result
| The test tube numbering | Cs (ml) | Normal saline (ml) | 2% cell suspension (ml) | 0.5 hour | 1 |
2 hours | 3 hours |
| 1 2 3 4 5 6 7 | 0.1 0.3 0.4 0.5 O distilled water 2.5 O.2 | 2.4 2.3 2.2 2.1 2.0 2.5 0 | 2.5 2.5 2.5 2.5 2.5 2.5 2.5 | ------+ | ------+ | ------+ | ------+ |
-, do not see haemolysis; +, haemolysis.
Table-4 vinorelbine liposome micro ball injections (Cz) hemolytic experimental result
| The test tube numbering | Cs (ml) | Normal saline (ml) | 2% cell suspension (ml) | 0.5 hour | 1 |
2 hours | 3 hours |
| 1 2 3 4 5 6 7 | 0.1 0.2 0.3 0.4 0.5 0 distilled water 2.5 | 2.4 2.3 2.2 2.1 2.0 2.5 0 | 2.5 2.5 2.5 2.5 2.5 2.5 2.5 | - - - - - - + | - - - - - - + | - - - - - - + | - - - - - - + |
One, do not see haemolysis; Ten, haemolysis.
The result shows: Cs, Cz do not see that haemolysis takes place, all qualified anaphylaxis experiment of the hemolytic experiment of two kinds of dosage forms
Get 8 of healthy guinea pigs, body weight 250-280g, male and female half and half, vinorelbine liquid drugs injection injection (Cs), two kinds of dosage forms of vinorelbine liposome micro ball injection (Cz) each 4 (male and female half and half), prepare by clinical practice dosage (30mg/ time) the conversion Cavia porcellus consumption (O.46mg/200g) of vinorelbine injection and with normal saline solution, the corresponding test liquid 0.5ml of every Cavia porcellus ip (lumbar injection), the next day once, totally three times.The the 14th, the 21 day corresponding reagent liquid 1ml (the dosage conversion is the same) that supplies of lateral vein injection outside the hind paw of every Cavia porcellus after injection first attacks.Each intravenously administrable was observed 2 hours, as two or more person who occurs grabbing in nose, perpendicular hair, cough, the dyspnea is judged to the positive; Be judged to the positive if any one of spasm, gatism, collapse, shock, phenomena of mortality person.The negative of above-mentioned symptom do not appear.
The anaphylaxis experimental result of two kinds of dosage form injection of vinorelbine is shown in table-5.
In the experimentation, Cs dosage group may be because the gastrointestinal irritation of medicine is excessive, causes the Cavia porcellus anorexia to detest water, diet initiatively not, respectively at different number of days death after the administration.(experiment triplicate)
Table-5 anaphylaxis experimental results
" feminine gender " expression is not irritated.
The result shows: two kinds of dosage forms of Cs, Cz all meet the anaphylaxis experimental standard.
Description of drawings
Fig. 1 LM structural representation
1 medicine, 2 lipid cores, 3 immobilized artificial membranes
Vinorelbine liposome micro ball injection change of granularity figure after Fig. 2 dilution
The specific embodiment
The prescription of vinorelbine preparation and preparation technology
Comparative Examples 1
Prescription 1:
Oil phase (soybean oil/MCT Oil=2/8) 10%
Vinorelbine 0.1%
Lecithin 1.2%
Glycerol 2.5%
Tween-80 0.2％
Enuatrol 0.1%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
Water for injection adds to 100ml
Preparation method 1:
(1) with lecithin, glycerol, Tween-80, the enuatrol of recipe quantity and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; (2) 10-hydroxyl-2-decylenic acid, the Span80 of recipe quantity added to 70-80 ℃ of mixing of heating in the mixing oil phase of injection soybean oil and injection MCT Oil, get oil phase: (3) add aqueous phase with oil phase, change in the tissue mashing machine, stirred for several minute, 1-5 time, until the oil phase homodisperse, get colostrum; (4) the vinorelbine drug powder is added this Ruzhong just, stirred 10 minutes, regulate about pH value to 8.5; (5) get above-mentioned colostrum add be preheated to 70-80 ℃ water for injection to full dose, be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (6) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Comparative Examples 2
Prescription 2:
Injection soybean oil 10%
Vinorelbine 0.1
Fabaceous lecithin 1.2%
Glycerol 2.5%
Tween-80 0.2％
Enuatrol 0.1%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
Water for injection adds to 100ml
Preparation method 2:
(1) Tween-80 of recipe quantity, enuatrol, fabaceous lecithin, glycerol are mixed with preheating 70-80 ℃ an amount of water for injection, change in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Simultaneously 10-hydroxyl-2-decylenic acid, Span80 are added to 70-80 ℃ of heating mixing in the recipe quantity soybean oil, get oil phase; (2) oil phase is added aqueous phase, change in the tissue mashing machine, stirred 10 minutes, 3 times,, get colostrum until the oil phase homodisperse; (3) the vinorelbine drug powder is added this Ruzhong just, stirred 10 minutes, regulate about pH value to 8.5, the water for injection that adds 70-80 ℃ of preheating is to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Comparative Examples 3
Prescription 3:
Oil phase (soybean oil/MCT Oil=2/8) 10%
Vinorelbine 0.1%
Lecithin 1.2%
Glycerol 2.5%
lween-80 0.2％
Enuatrol 0.1%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
Vitamin E 0.05%
Ascorbic acid 0.1%
Water for injection adds to 100ml
Preparation method 3:
(1) with lecithin, glycerol, Tween-80, enuatrol, the ascorbic acid of recipe quantity and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Simultaneously vitamin E, 10-hydroxyl-2-decylenic acid, Span80 are added to 70-80 ℃ of heating mixing in the recipe quantity oil phase, get oil phase; (2) oil phase is added to aqueous phase, changes in the tissue mashing machine, stirred 10 minutes,, get colostrum until the oil phase homodisperse; (3) vinorelbine is added to above-mentioned Ruzhong just, stir, regulate about pH value to 8.5; The water for injection that adds preheating 70-80 ℃ is transferred in the high pressure homogenizer to full dose, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (4) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Embodiment 1
Prescription 4:
Oil phase (soybean oil/MCT Oil=2/8) 10%
Vinorelbine 0.1%
Lecithin 1.2%
Glycerol 2.5%
Enuatrol 0.1%
Tween-80 0.2％
L0-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
Ascorbic acid 0.1%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100mL
Preparation method 4:
(1) recipe quantity lecithin, Tween-80, glycerol, enuatrol, ascorbic acid, the EDTA an amount of water for injection with preheating 70-80 ℃ is mixed, changes in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Simultaneously recipe quantity vitamin E, 10-hydroxyl-2-decylenic acid, Span80 are added in the mixing oil phase of being made up of injection MCT Oil, injection soybean oil, are stirred to complete mixing under heating 70-80 ℃, oil phase.(2) oil phase is added to aqueous phase, places high-speed tissue mashing machine's stirred for several minute, 3 times, colostrum.(3) vinorelbine is added so far in the colostrum, stirring and evenly mixing is regulated about pH value to 8.5, and the water for injection that adds preheating 70-80 ℃ is transferred to the high pressure homogenizer homogenizing 10 times to full dose.The sampling microscopy, to particle diameter below 0.3 micron; (4) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Prescription 5:
Injection soybean oil 10%
Vinorelbine tartrate 0.1%
Fabaceous lecithin 1.2%
Glycerol 2.5%
Tween-80 0.2％
Enuatrol 0.1%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
Sodium sulfite 0.2%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100ml
Preparation method 5:
(1) fabaceous lecithin of recipe quantity, Tween-80, enuatrol, glycerol, sodium sulfite, the EDTA an amount of water for injection with preheating 70-80 ℃ is mixed, changes in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Vitamin E, 10-hydroxyl-2-decylenic acid, Span80 with recipe quantity adds to 70-80 ℃ of heating for dissolving in the recipe quantity injection soybean oil simultaneously, gets oil phase; (2) oil phase is added aqueous phase, changes in the tissue mashing machine, stirred for several minute, 5 times, until the oil phase homodisperse, colostrum; (3) the recipe quantity vinorelbine tartrate is added to above-mentioned Ruzhong just, regulate pH value about 8.5, adding is preheated to 70-80 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Embodiment 3
Prescription 6:
Oil phase (soybean oil/MCT Oil=2/8) 10%
Vinorelbine tartrate 0.1%
Lecithin 1.2%
Glycerol 2.5%
Tween-80 0.2％
Enuatrol 0.1%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
L-cysteine 0.2%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100ml
Preparation method 6:
(1) lecithin of recipe quantity, Tween-80, enuatrol, glycerol, L-cysteine, the EDTA an amount of water for injection with preheating 70-80 ℃ is mixed, changes in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Simultaneously vitamin E, 10-hydroxyl-2-decylenic acid, the Span80 of recipe quantity added to 70-80 ℃ of heating for dissolving in the mixing oil phase of recipe quantity injection soybean oil and injection MCT Oil, oil phase; (2) oil phase is added aqueous phase, changes in the tissue mashing machine, stirred for several minute, 5 times, until the oil phase homodisperse, colostrum; (3) the recipe quantity vinorelbine tartrate is added to above-mentioned Ruzhong just, regulate pH value about 8.5, the water for injection that adds 70-80 ℃ of preheating is to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
| Sample | Outward appearance | PH value | Mean diameter | Zeta potential | Content (mg/ml) | Encapsulation ratio |
| Prescription 1 | Even emulsion | 8.45 | 175nm | -25.76 | 0.962 | 96.5 |
| Prescription | ||||||
| 2 | Even emulsion | 8.40 | 256nm | -27.85 | 0.973 | 92.3％ |
| Prescription 3 | Even emulsion | 7.36 | 212nm | -30.58 | 0.954 | 94.5％ |
| |
Even emulsion | 7.40 | 182nm | -32.56 | 0.925 | 96.3％ |
| Prescription 5 | Even emulsion | 8.36 | 259nm | -35.64 | 0.942 | 94.5 |
| Prescription | ||||||
| 6 | Even emulsion | 8.31 | 198nm | -26.15 | 0.978 | 98.8％ |
The sample room temperature of above-mentioned 6 prescription preparations was placed one month for 25 ℃, and every index is investigated as follows:
| Sample | Outward appearance | PH value | Mean diameter | Zeta potential | Content (mg/ml) | Encapsulation ratio |
| Prescription 1 | Even emulsion | 8.43 | 183nm | -25.50 | 0.764 | 95.0 |
| Prescription | ||||||
| 2 | Even emulsion | 8.37 | 270nm | -27.90 | 0.770 | 91.2％ |
| Prescription 3 | Even emulsion | 7.26 | 220nm | -29.58 | 0.845 | 93.8 |
| Prescription | ||||||
| 4 | Even emulsion | 7.24 | 185nm | -31.26 | 0.924 | 96.0％ |
| Prescription 5 | Even emulsion | 8.38 | 265nm | -34.48 | 0.941 | 94.0 |
| Prescription | ||||||
| 6 | Even emulsion | 8.28 | 199nm | -25.35 | 0.967 | 98.3％ |
| Sample | Outward appearance | PH value | Mean diameter | Zeta potential | Content (mg/ml) | |
| Prescription | ||||||
| 4 | Even emulsion | 7.20 | 188nm | -30.22 | 0.920 | 96.2％ |
| Prescription 5 | Even emulsion | 8.40 | 268nm | -35.48 | 0.940 | 93.8 |
| Prescription | ||||||
| 6 | Even emulsion | 8.23 | 212nm | -24.24 | 0.962 | 98.0％ |
| Sample | Outward appearance | PH value | Mean diameter | Zeta potential | Content (mg/ml) | |
| Prescription | ||||||
| 4 | Even emulsion | 7.16 | 193nm | -31.26 | 0.921 | 95.5％ |
| Prescription 5 | Even emulsion | 8.45 | 271nm | -35.20 | 0.937 | 93.0 |
| Prescription | ||||||
| 6 | Even emulsion | 8.22 | 215nm | -23.75 | 0.960 | 97.6％ |
Result: do not add sample (Comparative Examples 1 and the Comparative Examples 2) room temperature that the prescription of antioxidant and metal ion chelation agent makes and placed drug degradation about 20% one month for 25 ℃; Add antioxidant and do not add the sample room temperature that the prescription (Comparative Examples 3) of metal ion chelation agent makes and placed one month drug degradation about 10% for 25 ℃; Not only added antioxidant but also added the sample room temperature that the prescription (embodiment 1-embodiment 3) of metal ion chelation agent makes and placed one month for 25 ℃, medicine is degraded not.
Not only added antioxidant but add sample that the prescription (embodiment 1-embodiment 3) of metal ion chelation agent makes through 6 months every quality index of accelerated test all within acceptability limit; Keep sample 12 months result of the tests of room temperature show that every quality index is stable, all within acceptability limit, can fix tentatively 1 year its storage period.
Prescription 7:
Safflower oil 10%
Vinorelbine 0.05%
Lecithin 1.2%
Mannitol 3%
Cholic acid 0.1%
Poloxamer F68 0.2％
10-hydroxyl-2-decylenic acid 1%
Sodium pyrosulfite 0.1%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100mL
Preparation method 7:
(1) with recipe quantity lecithin, Poloxamer F68, mannitol, cholic acid, sodium pyrosulfite, EDTA and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine stirred for several minute, 5 times over to, disperse until each uniform ingredients, get water; (2) recipe quantity vitamin E, 10-hydroxyl-2-decylenic acid are added in the safflower oil, are stirred to complete mixing under heating 70-80 ℃, oil phase.(3) oil phase is added to aqueous phase, places high-speed tissue mashing machine's stirred for several minute, 5 times, colostrum.(4) vinorelbine is added so far in the colostrum, stirring and evenly mixing is regulated pH value to 8.5, and the water for injection dilution is settled to recipe quantity, is transferred to the high pressure homogenizer homogenizing 10 times.The sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Embodiment 5
Prescription 8:
Oil phase (Semen Coicis oil/Oleum Fructus Bruceae) 10%
Vinorelbine tartrate 0.1%
Lecithin 1.5%
Glycerol 2.5%
Tween-80 0.2％
Cholic acid 0.2%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.2％
L-cysteine 0.2%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100ml
Preparation method 8:
(1) with lecithin, L-cysteine, cholic acid, glycerol, EDTA, the Tween-80 of recipe quantity and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine, stirred for several minute, 1-5 time, disperse until each uniform ingredients, water; Simultaneously vitamin E, 10-hydroxyl-2-decylenic acid, the Span80 of recipe quantity added to 70-80 ℃ of heating for dissolving in the mixing oil phase of recipe quantity Semen Coicis oil, Oleum Fructus Bruceae, oil phase; (2) oil phase is added aqueous phase, changes in the tissue mashing machine, stirred for several minute, 5 times, until the oil phase homodisperse, colostrum; (3) the recipe quantity vinorelbine tartrate is added to above-mentioned Ruzhong just, regulate pH value 8.5, adding is preheated to 70-80 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Prescription 9:
Oil phase (soybean oil/MCT Oil=4/6) 10%
Vinorelbine 0.2%
Lecithin 1.2%
Glucose 5%
Enuatrol 0.01%
Poloxamer F68 0.2％
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.5％
Sodium sulfite 0.1%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100mL
Preparation method 9:
(1) with recipe quantity lecithin, Poloxamer F68, glucose, enuatrol, sodium sulfite, EDTA and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine stirred for several minute, 1-5 time over to, disperse until each uniform ingredients, get water; (2) recipe quantity vitamin E, 10-hydroxyl-2-decylenic acid, Span80 are added in the mixing oil phase of being made up of injection MCT Oil, injection soybean oil, are stirred to complete mixing under heating 70-80 ℃, oil phase.(3) oil phase is added to aqueous phase, places high-speed tissue mashing machine's stirred for several minute, 3 times, colostrum.(4) vinorelbine is added so far in the colostrum, stirring and evenly mixing is regulated pH value to 8.5, and the water for injection dilution is settled to recipe quantity, is transferred to the high pressure homogenizer homogenizing 10 times.The sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Embodiment 7
Prescription 10:
Oil phase (soybean oil/MCT Oil=2/8) 20%
Vinorelbine 1.0%
Fabaceous lecithin 1.2%
Glycerol 2.5%
Enuatrol 0.1%
Poloxamer F68 0.2％
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.5％
Sodium sulfite 0.1%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100mL
Preparation method 10:
(1) with recipe quantity fabaceous lecithin, PoloxamerF68, glycerol, enuatrol, sodium sulfite, EDTA and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine stirred for several minute, 5 times over to, disperse until each uniform ingredients, get water; (2) recipe quantity vitamin E, 10-hydroxyl-2-decylenic acid, Span80 are added in the mixing oil phase of being made up of injection MCT Oil, injection soybean oil, are stirred to complete mixing under heating 70-80 ℃, oil phase.(3) oil phase is added to aqueous phase, places high-speed tissue mashing machine's stirred for several minute, 5 times, colostrum.(4) vinorelbine is added so far in the colostrum, stirring and evenly mixing is regulated pH value to 8.5, and the water for injection dilution is settled to recipe quantity, is transferred to the high pressure homogenizer homogenizing 10 times.The sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Prescription 11:
Oil phase (Semen Coicis oil/Oleum Fructus Bruceae) 15%
Vinorelbine 0.5%
Fabaceous lecithin 1.5%
Glycerol 2.5%
Tween-80 0.2％
Cholic acid 0.2%
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
L-cysteine 0.2%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100ml
Preparation method 11:
(1) with fabaceous lecithin, Tween-80, glycerol, L-cysteine, cholic acid, the EDTA of recipe quantity and be preheated to 70-80 ℃ an amount of water for injection and mix, change in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Simultaneously vitamin E, 10-hydroxyl-2-decylenic acid, the Span80 of recipe quantity added to 70-80 ℃ of heating for dissolving in the mixing oil phase of recipe quantity Semen Coicis oil, Oleum Fructus Bruceae, oil phase; (2) oil phase is added aqueous phase, changes in the tissue mashing machine, stirred for several minute, 5 times, until the oil phase homodisperse, colostrum; (3) the recipe quantity vinorelbine is added to above-mentioned Ruzhong just, regulate pH value 8.5, adding is preheated to 70-80 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Claims (10)
1. lipide microsphere injection that contains vinorelbine is characterized in that the composition of injection is by weight percentage:
Vinorelbine 0.001%～10%
Oil-soluble medium 2%～50%
Surfactant 0.2%～10%
Osmotic pressure regulator 0.1%～10%
Oil phase solubilizing agent 0.1%～5%
Antioxidant 0.001%～2%
Metal-chelator 0.001%～2%
All the other are water for injection.
Wherein, vinorelbine is tartrate, maleate, lactate, malate, hydrochlorate, sulfate, the phosphate of vinorelbine;
Vegetable oil in the oil-soluble medium is a safflower oil, soybean oil, Semen Maydis oil, Semen Coicis oil, Oleum Fructus Bruceae, Oleum Ricini, Oleum Gossypii semen, Oleum Cocois, Petiolus Trachycarpi oil, MCT Oil MCT or its mixture; Animal oil is sebum, Adeps Sus domestica, fish oil, sperm oil and composition thereof;
Surfactant is that the phospholipid in the described surfactant is lecithin, fabaceous lecithin or its mixture;
Osmotic pressure regulator is a glycerol, sorbitol, mannitol, glucose or its mixture;
The oil phase solubilizing agent is 10-hydroxyl-2-decylenic acid, fatty acid esters of sorbitan Span or its mixture;
Antioxidant is water solublity antioxidant: sodium sulfite, sodium pyrosulfite, sodium sulfite, ascorbic acid, L-cysteine; Oil-soluble antioxidant: vitamin E or its mixture;
Metal-chelator is disodium EDTA EDTA, calcium disodium salt of EDTA or its mixture.
2. a kind of lipide microsphere injection that contains vinorelbine according to claim 1 is characterized in that; Phospholipid in the described surfactant is lecithin, fabaceous lecithin or its mixture; Tween in the described surfactant is a polysorbas20, polysorbate40, polysorbate60, Tween 80, polysorbate85, or its mixture; The pluronic of described surfactant is pluronic F68; Fatty acid esters of sorbitan Span in the described oil phase solubilizing agent is Span20,40,60,80, and perhaps its mixture.
3. a kind of lipide microsphere injection that contains vinorelbine according to claim 1 and 2 is characterized in that the vinorelbine of 90%-98% is wrapped in oil phase or the oil-water interfacial film in the injection.
4. a kind of lipide microsphere injection that contains vinorelbine according to claim 3 is characterized in that consisting of of this injection:
Vinorelbine 0.01%～5%
Oil-soluble medium 5%～30%
Surfactant 0.5%～5%
Osmotic pressure regulator 0.5%～5%
Oil phase solubilizing agent 0.2%～3%
Antioxidant 0.01%～1%
Metal-chelator 0.01%～1%
All the other are water for injection.
5. a kind of lipide microsphere injection that contains vinorelbine according to claim 4 is characterized in that consisting of of this injection:
Vinorelbine 0.05%～1%
Oil-soluble medium 8%～20%
Surfactant 1%～3%
Osmotic pressure regulator 1%～5%
Oil phase solubilizing agent 0.4%～2%
Antioxidant 0.05%～0.5%
Metal-chelator 0.02%～0.5%
All the other are water for injection.
6. a kind of lipide microsphere injection that contains vinorelbine according to claim 5 is characterized in that the composition of this injection is by weight percentage:
Vinorelbine 0.1%
The oil-soluble medium is soybean oil 2% MCT Oil 8%
Surfactant is lecithin 1.2%Tween-80 0.2% enuatrol 0.1%
Osmotic pressure regulator is a glycerol 2.5%
The oil phase solubilizing agent is 10-hydroxyl-2-decylenic acid 0.5%Span80 0.1%
Antioxidant is L-cysteine 0.2% vitamin E 0.05%
Metal-chelator is EDTA 0.05%
All the other are water for injection.
7. according to the preparation method of the described a kind of vinorelbine liposome micro ball injection of arbitrary claim among the claim 1-6, it is characterized in that comprising following steps: mix surfactant, osmotic pressure regulator, water solublity antioxidant, the metal-chelator of recipe quantity (1) with the water for injection that is preheated to 70-80 ℃, change in the tissue mashing machine, stir, until each composition dissolving, get water; With in the oil-soluble antioxidant of recipe quantity, the oil-soluble medium that the oil phase solubilizing agent adds to recipe quantity, be heated to 70-80 ℃ simultaneously, dissolving, oil phase; (2) oil phase is added aqueous phase, change in the tissue mashing machine, stir,, get colostrum until the oil phase homodisperse; (3) the recipe quantity vinorelbine is added to above-mentioned Ruzhong just, use sodium hydroxide, hydrochloric acid is regulated pH value 7-9, and adding is preheated to 70-80 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 1-10 time, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
8. the preparation method of the described a kind of vinorelbine liposome micro ball injection of claim 7 is characterized in that comprising following steps:
(1) surfactant, osmotic pressure regulator, water solublity antioxidant, the metal-chelator with recipe quantity mixes with the water for injection that is preheated to 70-80 ℃, changes in the tissue mashing machine, stirs, and until each composition dissolving, gets water; With in the oil-soluble antioxidant of recipe quantity, the oil-soluble medium that the oil phase solubilizing agent adds to recipe quantity, be heated to 70-80 ℃ simultaneously, dissolving, oil phase;
(2) oil phase is added aqueous phase, change in the tissue mashing machine, stir,, get colostrum until the oil phase homodisperse; (3) the recipe quantity vinorelbine is added to above-mentioned Ruzhong just, use sodium hydroxide, hydrochloric acid is regulated pH value 7-9, and adding is preheated to 70-80 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 1-10 time, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
9. the preparation method of the described a kind of vinorelbine liposome micro ball injection of claim 8 is characterized in that comprising following steps:
(1) surfactant, osmotic pressure regulator, water solublity antioxidant, the metal-chelator with recipe quantity mixes with the water for injection that is preheated to 70 ℃, changes in the tissue mashing machine, stirs, and until each composition dissolving, gets water; With in the oil-soluble antioxidant of recipe quantity, the oil-soluble medium that the oil phase solubilizing agent adds to recipe quantity, be heated to 70 ℃ simultaneously, dissolving, oil phase; (2) oil phase is added aqueous phase, change in the tissue mashing machine, stir,, get colostrum until the oil phase homodisperse; (3) the recipe quantity vinorelbine is added to above-mentioned Ruzhong just, use sodium hydroxide, hydrochloric acid is regulated pH value 8.5, and adding is preheated to 70 ℃ water for injection to full dose; (4) be transferred in the high pressure homogenizer, high pressure homogenize 10 times, the sampling microscopy, to particle diameter below 0.3 micron; (5) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
10. the preparation method of the described a kind of vinorelbine liposome micro ball injection of claim 9 is characterized in that comprising following steps:
Prescription is:
Oil phase: soybean oil/MCT Oil=2/8 10%
Vinorelbine 0.1%
Lecithin 1.2%
Glycerol 2.5%
Enuatrol 0.1%
Tween-80 0.2％
10-hydroxyl-2-decylenic acid 0.5%
Span80 0.1％
Ascorbic acid 0.1%
Vitamin E 0.05%
EDTA 0.05％
Water for injection adds to 100mL
Preparation method:
(1) recipe quantity lecithin, Tween-80, glycerol, enuatrol, ascorbic acid, the EDTA an amount of water for injection with preheating 70-80 ℃ is mixed, changes in the tissue mashing machine, stirred for several minute, 5 times, disperse until each uniform ingredients, water; Simultaneously recipe quantity vitamin E, 10-hydroxyl-2-decylenic acid, Span80 are added in the mixing oil phase of being made up of injection MCT Oil, injection soybean oil, are stirred to complete mixing under heating 70-80 ℃, oil phase.(2) oil phase is added to aqueous phase, places high-speed tissue mashing machine's stirred for several minute, 3 times, colostrum.(3) vinorelbine is added so far in the colostrum, stirring and evenly mixing is regulated about pH value to 8.5, and the water for injection that adds preheating 70-80 ℃ is transferred to the high pressure homogenizer homogenizing 10 times to full dose.The sampling microscopy, to particle diameter below 0.3 micron; (4) embedding is filled nitrogen in infusion bottle, places the high-pressure rotary steriliser to sterilize.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101155566A CN100375621C (en) | 2005-11-04 | 2005-11-04 | Vinorelbine liposome micro ball injection and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101155566A CN100375621C (en) | 2005-11-04 | 2005-11-04 | Vinorelbine liposome micro ball injection and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1771954A CN1771954A (en) | 2006-05-17 |
| CN100375621C true CN100375621C (en) | 2008-03-19 |
Family
ID=36759207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101155566A Expired - Fee Related CN100375621C (en) | 2005-11-04 | 2005-11-04 | Vinorelbine liposome micro ball injection and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100375621C (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101129375B (en) * | 2007-07-06 | 2010-12-22 | 浙江大学 | Vinorelbine solid lipid nano granule, freeze drying formulated product and method of preparing the same |
| CN101879138A (en) | 2009-05-06 | 2010-11-10 | 上海恒瑞医药有限公司 | Vinca alkaloid nano emulsion injection and preparation method thereof |
| CN101904814A (en) | 2009-06-04 | 2010-12-08 | 上海恒瑞医药有限公司 | Preparation method of drug loaded emulsion |
| CN103720653B (en) * | 2012-10-12 | 2016-01-20 | 天津药物研究院 | A kind of vinorelbine submicron emulsion injection and preparation method thereof |
| CN109350600B (en) | 2013-03-15 | 2021-10-29 | 台湾微脂体股份有限公司 | The composition of the aqueous and non-aqueous portions of the liposomes is designed to control the release profile of the drug |
| US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
| CN104706585A (en) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | Vinorelbine bitartrate fat emulsion concentrated solution, preparation method and application thereof |
| CN116546973A (en) * | 2020-11-19 | 2023-08-04 | 日本化药株式会社 | Composition containing water-soluble drug for causing vascular disorder, solution for preparing drug solution containing water-soluble drug for causing vascular disorder, kit, vascular disorder inhibitor, and solution containing nonionic surfactant |
| CN115645358B (en) * | 2022-09-09 | 2024-06-25 | 江苏豪森药业集团有限公司 | Vinorelbine tartrate injection and preparation method thereof |
| CN117462450B (en) * | 2023-11-24 | 2024-10-11 | 山东福瑞达生物股份有限公司 | Dual-modified 10-hydroxy-2-decenoic acid chitosan microsphere and preparation method and application thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446079A (en) * | 2000-06-30 | 2003-10-01 | 英耐克斯药品股份有限公司 | Liposomal antineoplastic drugs and uses thereof |
-
2005
- 2005-11-04 CN CNB2005101155566A patent/CN100375621C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1446079A (en) * | 2000-06-30 | 2003-10-01 | 英耐克斯药品股份有限公司 | Liposomal antineoplastic drugs and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1771954A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100375621C (en) | Vinorelbine liposome micro ball injection and its prepn | |
| CN102159187B (en) | A nano-emulsion injection of vinca alkaloids and the preparation method thereof | |
| HU196700B (en) | Process for producing parenterally administrable, homogenized pharmaceutical compositions in emulsion form, comprising basic hydrophobic active ingredient | |
| CN101288642B (en) | Taxanes medicine preparation for intravenous injection and preparation method thereof | |
| CN109310643A (en) | The dutasteride and Tadalafei compound formulation of ester derivant containing glycerine fatty acid or methyl glycol fatty acid ester derivative and the oral capsule preparation comprising it | |
| CN1985851B (en) | Lipoid microsphere injection containing toad cake extract and its preparing method | |
| CN102319214B (en) | Lipid microsphere injection containing sodium demethyl cantharidate-phosphatide complex and preparation method thereof | |
| CN102552137B (en) | Triptolide fat emulsion injection and preparation method thereof | |
| CN101869302B (en) | Micro-emulsion calcium preparation and preparation method as well as application thereof | |
| CN102552293B (en) | Compound vitamin submicron emulsion lyophilized powder for injection and preparation method of compound vitamin submicron emulsion lyophilized powder | |
| CN105456200B (en) | A kind of preparation method and application for the nano mciroball improving insoluble drug oral administration biaavailability | |
| CN101601649B (en) | Ubenimex fat emulsion injection and preparation method thereof | |
| CN101332176A (en) | Medicine composition for injecting cinnarizine lipid microsphere and preparation method thereof | |
| CN111481640B (en) | Anti-liver cancer microemulsion nano composition and application thereof | |
| CN1813733A (en) | Vitamin E nicotinate lipide microsphere injection and its preparing method | |
| CN101204373A (en) | Paclitaxel lipid microspheres injection and preparation method thereof | |
| CN101797228B (en) | Method for preparing oryzanol microemulsion | |
| CN101322688B (en) | Flumazenil oil-in-water emulsion for vein and preparation thereof | |
| CN100515389C (en) | Medicinal emulsion adapted for difficultly soluble medicine and method for preparing the same | |
| CN105311622B (en) | A kind of combination medicine that treating pain and its preparation, preparation method | |
| CN1973826A (en) | Injection containing lipoid microsphere of etoposide and its prepn process | |
| CN102258467B (en) | Formula and preparation of intravenous injection sustained-release fat emulsion of arteannuin and derivative thereof | |
| CN101461782B (en) | Sub-microemulsion preparation for levocarnitine injection and preparation method thereof | |
| CN1846776B (en) | Injection of long-chain fat from zedoary oil and its preparation process | |
| CN101332186A (en) | Medicine composition for injecting triamcinolone acetonide palmitate lipid microsphere and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Beijing Boshi Antai Technology Co., Ltd. Assignor: Tang Xing|Zhao Shaochun|Qi Xinguo Contract fulfillment period: 2009.8.20 to 2014.8.20 Contract record no.: 2009990001191 Denomination of invention: Vinorelbine liposome micro ball injection and its prepn Granted publication date: 20080319 License type: Exclusive license Record date: 20091026 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.8.20 TO 2014.8.20; CHANGE OF CONTRACT Name of requester: BEIJING BOSHI AETNA SCIENCE AND TECHNOLOGY DEVELOP Effective date: 20091026 |
|
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHAO SHAOCHUN QI XINGUO Effective date: 20150114 Owner name: SHENYANG DONGXING PHARMACEUTICAL TECHNOLOGY CO., L Free format text: FORMER OWNER: TANG XING Effective date: 20150114 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 110015 SHENYANG, LIAONING PROVINCE TO: 110000 SHENYANG, LIAONING PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150114 Address after: Wavesource street in Dongling District of Shenyang city in Liaoning province 110000 19-1 block A room 201-17 Patentee after: Shenyang Dongxing Medical Technology Co., Ltd. Address before: 110015 No. 103, Wenhua Road, Shenhe District, Liaoning, Shenyang Patentee before: Tang Xing Patentee before: Zhao Shaochun Patentee before: Qi Xinguo |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080319 Termination date: 20181104 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |